Summary of main recommendations
1 CLiNICAL USE The main application for routine progesterone assays in the clinical chemistry laboratory is for the confirmation of ovulation and the assessment of the adequacy of the luteal phase. Routine estimations during pregnancy should not be undertaken.
CRITERIA TO PERFORM PROGESTERONE

ASSAYS
In general, laboratories should not consider establishing progesterone assays unless they would receive more than about 50 requests each' month. Results should be available within 2 weeks. Laboratories must be members of the NEQAS progesterone scheme and must meet the criteria laid down for acceptable performance.
3 CHOICE OF REAGENTS Laboratories with expertise in developing their own in-house immunoassay methods should consider an in-house non-extraction technique.
Laboratories with inadequate performance with extraction assays, tritium label and charcoal-dextran separation should consider changing to an iodine-125 label with a more robust separation method, but retaining extraction.
Those laboratories with little or no experience in steroid radioimmunoassay must take care to choose a direct assay kit which is capable of achieving a consistently acceptable performance in the NEQAS scheme. At present, evidence suggests that only one kit is This paper was prepared at the invitation of the Analytical Methods Working Party of the Scientific Committee of the Association of Clinical Biochemists but does not necessarily reflect the views of the Scientific Committee. capable of achieving the 'criteria for adequate performance ( Table 2) .
The NEQAS organiser is always willing to advise on the appropriate choice of method.
Introduction
This paper reports on the deliberation of a group of scientists on the measurement of progesterone. The aims were: to give general guidance on factors which influence the assay, to survey available methods, to make recommendations on available kits and in-house methods and to advise on those criteria which laboratories should consider before setting up progesterone assays.
Clinical applications for progesterone assays
Serum or plasma progesterone assays have been used since the mid 1970s as an indication of ovulation and for the investigation of the control of the ovarian cycle. There is still uncertainty about the amount and time-scale of progesterone secretion which is necessary to sustain a normal pregnancy. The reader is referred to a recent review for a detailed discussion of the clinical aspects of progesterone analysis.' DETECTiON OF OVULATiON This is the major application for plasma progesterone estimations. Although basal body temperature measurements have been used as an indication of ovulation, results may be difficult to interpret and give information mainly about the duration of the luteal phase. Plasma
LUTEAL PHASE INSUFFICIENCY (LPI)
The 'short', 'inadequate' or 'defective' luteal phase has been associated with 3·4% of all infertility cases, and with 35% of cases of early abortion. 10 The pathophysiology and diagnostic criteria associated with this syndrome are, however, poorly defined. Several approaches have been used to identify LPI, including multiple progesterone sampling during the luteal phase, histological dating of endometrial biopsy tissue or basal body temperature charting. Strott et alY have stated that the sum of taken around the mid-luteal peak (on days 19, 21 and 23, for example) may provide more information. For all these measurements, interpretation depends upon correct assessment of time from the start of the last menstrual period just as much as on precise and accurate progesterone assays.
A healthy mid-luteal progesterone concentration indicates luteinisation of the follicle and is only presumptive evidence of release of an ovum. Studies in which plasma progesterone concentrations have been correlated with laparoscopic confirmation of a ruptured follicle have shown that luteinisation of the follicle without release of the ovum (the 'luteinised unruptured follicle syndrome') may be more frequent in infertile patients than was previously suspected. s-a In this syndrome plasma progesterone concentrations, although 'they reflect luteinisation, give a false indication of ovulation. It has been established that less progesterone escapes into the peritoneal fluid from the corpus luteum if the ovum is not released.f
Hull et al? studied 212 cycles in women prior to their treatment for infertility and noticed that there was a lack of subsequent conceptions for both low and high extremes of progesterone concentrations. Too high a mid-luteal progesterone concentration (probably greater than ,100 nmol/L) may therefore be associated with infertility in untreated patients.
Plasma progesterone concentrations in cycles in which conception occurs after clomiphene or gonadotrophin therapy are higher than in 'untreated' cycles by factors of 1·5 and 3 respectively." 9 These higher concentrations result from production by multiple follicles, and it may be necessary to aim for higher progesterone concentrations when ovarian stimulation is employed. The criterion of a mid-luteal plasma progesterone result of greater than 30 nmol/L may not be a reliable indicator of ovulation in these cases. Results from nine women were obtained with a 'direct' assayusing12SI-tracer. This assay showsclose agreement with extractionPH-tracer methods. Data for the remaining 45 women were obtained with extractionPH-traccncharcoal separation assays.
progesterone concentrations in healthy regularly menstruating women are shown in Fig. 1 , synchronised to the. mid-cycle LH peak. In the follicular phase (days 1-11), concentrations are usually less than 3 nmol/L, the detection limit for many routine progesterone assays. The use of more sensitive assays has shown that in healthy, regularly menstruating women levels rise slightly before the mid-cycle LH surge. This rise in progesterone just before the LH peak may play a part in potentiation of gonado-. trophin release. 2. -3 Following the mid-cycle gonadotrophin surge there is a sharp rise in plasma progesterone concentration to reach a mid-luteal peak of 3D-80 nmol/L usually between days 19-23 of the cycle (Fig. 1 ).
It is difficult to define a limit for mid-luteal progesterone concentrations above which ovulation can be said to have occurred. Ovulation is more likely with increasing progesterone concentration, with a high probability when mid-luteal progesterone concentrations are more than 30 nmol/L, Ovulation is unlikely to have occurred if mid-luteal progesterone concentrations are below 10 nmol/L.
To confirm that ovulation has occurred, a single plasma progesterone estimation on a mid-luteal specimen is a clinically useful criterion. 4, 5 However, if luteal phase insufficiency is suspected, three or more samples · three progesterone results taken during the luteal phase should be greater than 48 nrnol/L in a normal luteal phase. It is possible that LPI results from one or more factors such as failure of proper development of the corpus luteum, normal corpus luteum but inadequate progesterone synthesis or resistance by the uterus to the action of progesterone. A further possibility is that the luteinised unruptured follicle syndrome may be associated with delayed progesterone production and a shortened luteal phase."
There is evidence that, in the investigation of LPI, measurement of both progesterone and oestradiol in the luteal phase gives more information than progesterone concentrations alone. Patients with low mid-luteal progesterone and high oestradiol concentrations have good ovulatory responses. 12
PROGESTERONE MEASUREMENTS IN
PREGNANCY
Plasma progesterone measurements have been used in the first trimester of pregnancy as an indication of the outcome of threatened abortion, but there is little evidence that these are worthwhile except as a research tool. Discussion with clinical colleagues has confirmed our' view that there is no justification for the routine estimation of plasma progesterone concentrations in pregnancy. Several manufacturers list the measurement of progesterone in early pregnancy as an application for their kits; users should beware the introduction of progesterone assays for this purpose.
IN-VITRO FERTILISATION
Some research centres use progesterone assays in the late follicular phase to predict the mid-cycle gonadotrophin surge. At present it is not clear whether progesterone measurement offers advantages over measurement of oestrogens or oestrogen conjugates, which are also used for this purpose.
CIRCADIAN RHYTHMS
There is little evidence for a circadian rhythm in plasma progesterone in women, although there is one report suggesting its occurrence around ovulation.':' In men, progesterone concentrations are low (less than 1 nmoVL); a circadian rhythm in plasma progesterone (presumably of adrenal origin) has been reported to correlate with that in plasma cortisol. 14 During pregnancy large variations have been recorded with Progesterone assay guidelines 3 low values in the morning, but there is also large sample-to-sample variability. 15, 16 AGE AND ETHNIC GROUP Plasma progesterone concentrations average 0·5 nmol/L in infants less than 25 weeks old, and 0·3 nrnol/L in older infants. In girls, progesterone concentrations show a small increase with advancing bone age and there is a weak correlation with the stage of puberty. Boys have concentrations of about 0·4 nrnol/L until the age of 16 with a small increase to 0·7 nrnol/L from 16 to 19 years; no correlation with stage of puberty has been noted. I? 18 During the perimenopause some cycles may have normal luteal phase progesterone secretion in the presence of decreased oestradiol production. Later cycles show decreased secretion of both steroids. Postmenopausal progesterone concentrations are low and are thought to result mainly from adrenal secretion.
There is no evidence of ethnic differences in plasma progesterone concentrations during the ovulatory cycle.
SALIVARY PROGESTERONE ASSAYS
Venesection requires trained staff, is uncomfortable and stressful for the patient and often presents difficulties in children. In contrast the collection of saliva is simple, stress-free and can be repeated at frequent intervals.
Measurement of hormones and drugs in saliva is being increasingly used as an effective alternative to blood assays for low molecular weight analytes. 1~21 Changes in salivary concentration parallel those in serum, and salivary steroid concentrations show relatively greater responses in dynamic endocrine tests. Salivary concentrations of neutral steroids are independent of salivary flow rate.
The problem of handling viscous saliva specimens can be avoided by freezing and thawing; precipitated mucins and glycoproteins sediment out, leaving a clear supernatant. Negligible hormone losses occur.
Limitations of the technique
Concentrations of steroid hormones in saliva are less than 10% of those in serum. Assays with lower detection limits are needed, and maintenance of assay control at these low concentrations is more difficult. Optimisation of salivary assays must be thorough; it is usually necessary to prepare standards in buffer, leng-then the incubation period, use different antibody dilutions and increase sample volume.
Interference by food and drink debris can be avoided by collecting samples after subjects have rinsed their mouths with water. Blood contamination of the sample from infected gums or over-vigorous brushing of the teeth can cause serious over-estimation of hormone concentrations. Some centres prefer a test for occult haemoglobin before assaying samples.
The major problem associated with employing salivary assays is the large increase in workload that may result. At least ten times the number of salivary specimens may be expected in the study of female infertility, and a reasonable degree of automation is required for routine salivary steroid assays.
Criteria for a progesterone assay service
Any laboratory setting up progesterone assays should first establish the particular clinical setting(s) in which results are to be used. The major clinical implications have been set out above, and the quality-assurance criteria outlined here relate to the investigation of ovulation and measurement of progesterone in the luteal phase. The information on request cards must be examined to ensure that samples are not being sent to the laboratory for other reasons, where the assay may be invalid.
The following criteria should be fulfilled for any laboratory to set up a progesterone assay:
(1) The minimum number of samples to establish an economical and technically viable assay is about 50 per month; assays should not be set up where the majority of samples are internal and external quality-assessment.
(2) Two weeks is considered as the maximum acceptable turn-around time.
(3) All NHS laboratories measuring serum progesterone for the monitoring of ovulation must be members of the National External Quality Assessment Scheme.
(4) Internal QC should involve assay of progesterone in control samples with three different concentrations. Assays should be optimised to provide best precision in the range 1D-40 nrnol/L, Between-batch coefficients of variation should be less than 10% over this range. Laboratories should meet the performance criteria laid down by the Steering Committee for the NEQAS steroid schemes; for progesterone unacceptable performance has been defined as a bias or variation of the bias of greater than 20%.
(5) It is advisable to aim for methods which overall produce results within ± 15% of the ALTM. The Steering Committee has defined acceptable performance as a bias of less than ±20% of the ALTM.
(6) All estimations for standards, control sera and unknown serum samples should be carried out in duplicate. (7) Acceptable extraction of tritiated progesterone is between 90 and 105% of theoretical, with less than 5% variation between samples.
(8) Non-specific binding should be 6--7% at worst; ideally it should be less than 5%.
(9) For ovulation monitoring cross-reactivity to cortisol should be less than 1%; for direct assays the cross-reaction to progesterone glucuronides should be less than 5%.
(10) The regression line for a serial dilution experiment should not deviate from the theoretical line by more than twice the standard deviation at each concentration. (11) Recovery experiments for at least three concentrations should be between 90 and 105% using patient samples.
(12) The concentration indicated by blank experiments (solvent blanks for extraction, stripped plasma or buffer for direct methods) should be less than 2 nmol/L, Methods should be able to indicate reliably concentrations of 5-10 nmoUL.
Performance of methods in the National External Quality Assessment Scheme
At present there are 86 laboratories participating in the progesterone NEQAS scheme (see Appendix 1), using 13 different methods listed in Table 1 . Of these laboratories, 28 use extraction techniques and 58 non-extraction methods. The performance achieved by these different methods are shown by BIAS and VAR in Table 2 , for those laboratories which had used the same method for at least 6 months up to October 1983. Only 70% of laboratories were able to perform adequately with regard to bias from the ALTM, and only 55% with regard to VAR. Examination of Table 2 demonstrates that almost all laboratories using direct methods developed in-house and DPC kits consistently achieved the required standard. Of the in-house extraction assays, half gave unacceptable performance, while the evidence is that at the moment the NETRIA, Hoechst, and Serono direct kits give unacceptable performance. There are a few laboratories using other Laboratories have been included only when no method change has occurred within the previous 6 months. methods (Farmos, Nordiclab and NMS), and while there is insufficient evidence to adequately assess their performance at present, only one of five laboratories using these kits achieved satisfactory performance. It is difficult to identify reasons for the poor performance of some kits without detailed information on the methods used. However, problems of standardisation, sample 'matrix' effects, the quality of the radioactive tracer, techniques of progesterone displacement and interference by synthetic progestagens have been identified in different kits. 22 Given the considerable method-related differences in bias which are apparent in NEQAS reports, a reference method which unequivocally provides a 'target' concentration for progesterone QA pools seems highly desirable. At present there are problems in assessing bias because reference target levels are not available; the problem with using the ALTM is that it may be sensitive to changes in the number of laboratories using particular methods. Gas chromatography combined with mass spec- 
Laboratories have been included only when no method change has occurred within the previous 6 months. trometry fulfills the requirements of a reference method, and NEQAS pools with assigned GCMS targets are only recently available.
GCMS target values should be available for NEQAS pools. It would then be possible to compare performance measurement based on both ALTM and GCMS targets. After a suitable period of time, a decision could then be made as to whether GCMS target values should be used for the assessment of bias, and whether this will aid improvements in laboratory performance and comparability of results.
StafTmg and methods for progesterone assay STAFF TRAINING
Laboratories with no previous experience in this type of assay should send at least one member of staff to recognised RIA training courses. These are regularly advertised in the various professional journals, and may be at North East London Polytechnic, University of Surrey, or at one of the Supraregional centres. Should none of these be available, then training should be sought at specialist laboratories by enquiry, for instance, through a NEQAS organiser. Ideally several members of staff should attend such courses over a period of years.
Once established, it should be recognised that steroid immunoassays require special skills. They are not tests which can be picked up immediately by even the most experienced laboratory staff. Assayists should be given thorough and adequate training and familiarisation before working with clinical samples. It is good practice for trained personnel to run the assay routinely for several months while the laboratory becomes familiar with the technique. Rotation to and from steroid immunoassays should not be too frequent; it has long been recognised that this is one of the major causes of laboratory imprecision. More robust assays will be less affected by staff changes, but rotation at frequent intervals (less than 3 months) may lead to poor performance.
IN-HOUSE METHODS: EXTRACTION
TECHNIQUES 'Progesterone in plasma or serum is bound to a number of endogenous binding proteins including corticosteroid-binding globulin (CBG) and albumin.P Just as with the assay of other small molecular weight hormones, these endogenous binding proteins can interfere with radioimmunoassay. Some way of obviating their effects must therefore be sought; organic solvent extraction is one technique.
The progesterone molecule has low polarity and consequently may be extracted from plasma or serum by organic solvents such as hexane or petroleum ether (b.p. 4G--60°C); this will achieve a partial separation of progesterone from more polar steroids." Serum samples (typically 100 !1L) should all be extracted simultaneously by vigorous mixing or shaking for several minutes with an excess of solvent (at least a twentyfold excess). This may be conveniently performed on an apparatus such as the SMI multivortex mixer. The duration and vigour of the extraction should remain constant.
Extraction efficiency depends upon the choice of solvent and method used. Ideally it should be complete, but if recovery is less than 90% or variable, then extraction efficiency should be determined for each sample. This is done by adding a small amount (1000 dpm) of [3H]progesterone as internal standard before extraction (see Appendix 2) .
Removal of the solvent is achieved after separation of the phases by immersion of the extraction tube in freezing mixture (solid CO 2), and then decanting the solvent into the assay tube. Alternatively, aliquots of solvent phase may be carefully pipetted. Complete solvent evaporation is achieved in an air or nitrogen stream for the minimum required time (less than 30 min) at temperatures less than 60°C; alternatively, instruments which employ heat, vacuum and vortexing together (Buchler Vortex Evaporator) may be convenient. Losses may occur if residues are left for long periods before solubilisation. Further purification of the sample extract is unnecessary when a specific antiserum raised to a ll-ahydroxyprogesterone hemisuccinyl conjugate is used. These antisera are, in general, of good specificityv and readily available.
Progesterone in ethanolic solution (warmed to room temperature) is used for assay standardisation. Residues of the extraction solvent can inhibit specific binding in the assay." Progesterone standard curves should compensate for this effect by including solvent residues. Alternatively, some centres prefer to make up progesterone standards in male serum which can be extracted along with test specimens. Either method is suitable.
Tritiated progesterone has been the label of choice over the last 10 years, although more assays now use iodine-125Y-29 Assays for clinical application have recently been developed using enzyme ,311 fluorescenr" and chemilurrunescent'" labels, but none of these is in general use.
Dextran-coated charcoal has been the conventional separation technique.i" particularly for assays using tritiated labels. However, there are a number of technical problems associated with this method. Different separation characteristics may be produced by different batches of charcoal and dextran, or by different ratios of charcoal to dextran. The separation should be conducted at low temperature to prevent dissociation of antibody-bound progesterone after removal of the free steroid which binds to the charcoal. A refrigerated centrifuge should always be used to sediment the charcoal. The time of the incubation with charcoal-dextran may be critical, and can limit batch size in order Progesterone assay guidelines 7 to prevent drift within an assay. Some of these problems may be overcome in part by the advent of magnetised charcoal which obviates the requirement for a centrifuge. Recently, however, double antibody.i? solid-phase" and magnetisable solid-phase separation methods have been introduced in an attempt to improve precision.
Several of the problems inherent with assays using tritiated label and dextran-coated charcoal separation can be overcome by the use of 
IN-HOUSE METHODS: DIRECT TECHNIQUES
In order to measure progesterone directly without extraction, the steroid must be displaced from its binding proteins. Displacing reagents which interact with the progesterone binding sites include danazol at 400 ngl tube,33, 34 cortisol at 200 ng/tube" and 8anilino-naphthalene sulphonic acid (ANS) at 400 ,...gltube. 36 These amounts of displacing reagent have been found to produce optimal displacement for a sample volume of 50 ,...L. Whether these conditions provide complete displacement in states of elevated CBG has not been established. Effective displacement is also achieved at pH 4·0 in the presence of 36 ,...g ANS 34 and at pH 10·0 with 50 ug ANS, although there may be some reduction in specific binding compared with assays at neutral pH. At present the displacing conditions of choice and the assay system yielding the best performance remain to be identified. The majority of laboratories employ danazol, and this has the advantage that it is a synthetic steroid with high affinity for CBG,37 it does not significantly cross-react with most progesterone antisera and has less effect on specific binding than either cortisol or ANS. Danazol may be obtained from the Medical Information Department, Winthrop Laboratories, Sterling-Winthrop House, Surbiton, Surrey.
To date only tritium, iodine and enzyme labels 38 have been used in direct assays, though a growing and significant proportion of inhouse assays. in the U~are direct methods using a combination I of antisera raised to 11-a-hemisuccinyl conjugates and P25I]pro §;sterone-glucuronyl-tyramine (PGT) label. 29 , This heterologous bridge system has been shown to yield sensitive and precise assays with steep dose-response curves, well suited for direct assay methods. A number of antisera from different sources previously employed for extraction assays have been found to yield satisfactory direct assays using [ 125I]PGT.
Although the majority of in-house direct assays have been in use for 1 or 2 years, experience suggests that the potential for improved performance can be impaired unless care is taken in the purification of [ 125I]PGT. PGT is iodinated directly using chloramine-T or iodogen, and purification of the reaction product yields several peaks of activity.39 Care should be taken to separate these components and to select the peak with highest immunoreactivity (> 90% bound to excess antiserum). A suitable tracer, prepared by highperformance liquid chromatography, is now available from Amersham International.
Problems can also arise in the standardisation of direct assays. Most use progesterone standards prepared in serum matrix and the majority of laboratories have achieved satisfactory standardisation using pooled male serum which has a progesterone concentration of less than 1·0 nmol/L as a base material. 34 Individual sera should be screened before pooling, rejecting any which give significant inhibition over the standard zero dose tube. Laboratories should check the accuracy of their assay by preparing recovery pools from a serum pool spiked with different levels of progesterone.
IN-HOUSE METHODS: NON-ISOTOPIC
TRACERS
All non-isotopic assays for progesterone in the literature are extraction methods and all require a separation step--they are heterogeneous assays. Of those advocated for routine clinical application there is greatest experience with enzyme immunoassays. The combination of the label progesterone 11-ahemisuccinate coupled to horseradish peroxidase with a low molar incorporation ratio and an antiserum raised to a progesterone 11-ahemisuccinyl conjugate yields assays similar in sensitivity to typical radioimmunoassay methods.P Other non-isotopic extraction assays recently described include a fluoroimmunoassay" using progesterone-3-carboxymethyl oxime coupled to fluoresceineamine as label and with separation by ammonium sulphate or magnetisable solid phase. In a chemiluminescent assay32 the antiserum is coated to polystyrene tubes and the tracer is a progesterone ll-a-succinylisoluminol derivative. End-point detection involves solubilisation of the antibody-bound fraction in alkali followed by the addition of microperoxidase and hydrogen peroxide to initiate chemiluminescence. Automated luminometers capable of performing automated analyses are becoming available, and while non-isotopic methods are probably regarded as specialist techniques now, a few years may see their introduction for the routine analysis of several analytes.
KIT METHODS
A comprehensive review of the kit methods available: in the UK for progesterone measurement is provided in Tables 3 to 9. The Tables list the methods and manufacturers and attempt as full a description as possible of the reagents and conditions. Inevitably these will be a little . out of date as progesterone methods are changing rapidly.
In choosing a particular kit from this range several points should be considered. Frequently kits are evaluated by NEQAS schemes; a list of reports is given in Appendix 3. Some methods have been shown to perform particularly well, and kits found to perform well in evaluations also do so in general use. For steroid assays there is often substantial bias between methods, and this is particularly true for kits; it would be prudent to avoid kit methods which demonstrate significant bias from the ALTM.
Comparative merits of kits and in-house methods
An important consideration in the identification of methods most suited for clinical application relates to their analytical performance. There is evidence from NEQAS that several different types of assay are capable of achieving the desired performance defined by the Steering Committee for Steroids, although not all laboratories using a given method achieve a similar level of performance.
Other factors to be considered in assessing Costlkit is basic cost excluding VAT, shipping costs or discounts. Discounts are usually available for standing orders, bulk purchases of the kit or mixed bulk purchases of kits for various analytes. The volume of reagents provided in each kit listed above is given for the smallest kit available, i.e. 100-or 125-tube size. The volumes shown apply to available reagent i.e. after reconstitution if necessary. Data given in the table was obtained from protocol sheets provided by the manufacturers and although believed to be correct may contain discrepancies due to modifications by manufacturers. Lack of data in the table indicates that item is not supplied or the information was not available for inclusion. the comparative merits of available methods include practicability, expertise required and cost. Examples of reagent costs for three different in-house assays are given in Table 10 . The expertise required to validate an in-house assay and maintain its performance is significantly greater than with some of the kits now being produced; this factor may ultimately determine the method most suitable for a particular laboratory. Time spent in reagent preparation and assessment, as well as standardisation, is greater with in-house assays, although the time taken for the assay itself need not necessarily be greater. Available equipment may also be a significant determining factor. Methods which need refrigerated centrifuges or beta-counters will inevitably add to overall assay complexity when compared to those Cost/kit is basic cost excluding VAT, shipping costs or discounts. Discounts are usually available for standing orders, bulk purchases of the kit or mixed bulkp urchases of kits for various analytes.T he volume of reagents provided in each kit listed above is given for the smallest kit available i.e. 100 or 125-tube size.
.....
The volumes shown apply to available reagent i.e. after reconstitution if necessary.
..... Data given in the table was obtained from protocol sheets provided by the manufacturers and although believed to be correct may contain discrepancies due to modifications by manufacturers. Lack of data in the table indicates that item is not supplied or the information was not available for inclusion. which can use multihead gamma-counters and perhaps need no centrifugation. Major disadvantages of typical extraction assays employing a tritium label and charcoal separation include equipment requirements and technical complexity discussed earlier. With these assays there is more possibility of experimental error; in addition there is the difficulty of work simplification of the extraction step, the hazards which arise from the use of solvents as well as the inconvenience and cost of beta-counting. These assays have a relatively small sample capacity (usually only about 20-30 specimens); this is partly a reflection of problems with extraction and partly to reduce within-batch drift arising from charcoal separation.
Extraction assays using iodine-125 tracers and improved separation methods offer advantages of convenience of gamma counting and reduction in assay drift, allowing larger numbers of specimens to be analysed. They are therefore a suitable choice for the laboratory which has previously used extraction assays with tritium labels and does not wish to buy commercial direct assay kits.
The major advantages of direct assays using iodine tracer and solid-phase or doubleantibody separation methods over conventional extraction assays with tritium labels relate primarily to technical simplicity. Direct methods are simple to perform and offer the possibility of automation. Sample capacity is up to fivefold greater. Although iodine labels are expensive, this is more than offset by cost saving of gamma-over beta-counting. Evidence from a number of laboratories with in-house direct assays and from NEQAS indicates that direct assays can be specific, accurate and precise, and can cover a working range from 2 to 100 nrnol/L with a 50 ilL sample volume.
Non-isotopic tracers have the advantage of a long shelf life and are free from any hazards associated with radioactivity. Their use at present has been restricted to a small number of laboratories, but experience suggests that as yet the methods do not offer significant advantages of performance or convenience compared with . isotopic methods. In addition, these techniques require specialised equipment for measuring fluorescence or luminescence; although automated equipment is becoming available, the currently available range of assays is limited, and it will probably be some time before non-isotopic methods enter general use. Within the last year, kit methods using direct techniques for progesterone assay have become available, and as a result kits are being used in more laboratories than formerly. The best kit methods are simple, precise, accurate and robust. The simplest kit currently available requires only two pipetting steps into coated tubes and a single 3-hour incubation at ambient temperature; no centrifugation is required.
There are however difficulties with kits in their standardisation and bias. With the exception of NETRIA no kit is manufactured in the UK and most are sold through distributors. Understandably, therefore, the suppliers are sometimes unable to respond adequately to queries about standardisation, bias, or poor performance. Large scale bias from ALTM or GeMS target values is the major complicating factor in meeting criteria for adequate perform-ance in steroid NEQAS. Kits with marked bias from the ALTM should be avoided.
Kits are expensive when they are compared with the reagent costs of in-house assays. Because of the cost, it is not infrequent for laboratories to attempt to economise either by performing assays once rather than in duplicate or by using smaller amounts of reagents than those indicated by the manufacturer. This 'stretching' of kits by use of half, quarter, or even smaller amounts of reagents is frequently done without any attempt to assess the assay performance under these altered conditions; to do so would involve almost as much work as setting up an in-house method, and would be expensive. There is no definitive indication of the extent to which 'stretching' effects assay performance, but this practice should be avoided. 
Internal quality assurance
Quality-assurance procedures can provide information on the main sources of laboratory error. These include random errors or blunders, systematic error or bias, and intrinsic variability of the method, an index of which is precision. Pr.ecisionis best determined by internal QC, whilst external quality assessment is essential for the estimation of bias. Proper internal QC should allow the operator to accept or reject individual results or batches according to predetermined criteria appropriate to the clinical applications of the assay. The principles and practice of internal QC have been described in detail for immunoassays.~2 Useful practical information may also be gained from monographs produced by commercial manufacturers" 4:1 Although data reduction for radioimmunoassay methods can be derived manually, significant benefits are achieved by using computers for calculating dose-response curves and many aspects of QC. Programs written especially for microcomputers are available from Professor R P Ekins, Middlesex Hospital, London, Bioanalysis, Cardifr4 and commercial sources.
An excellent text with an extensive programmed learning course on all numerative aspects of immunoassay also exists.'s PRECISION Outliers or gross random errors can be identified from the difference in duplicates, e.g. greater than 5-10%, and, depending on the clinical significance of the result, re-assay may be indicated. Analysis of the error of all duplicate counts in the assay yields an average batch coefficient of variation.t" but this does not provide a dose-related estimate of precision. Within-and between-batch precision can be assessed by including in each batch pools with low, medium and high concentrations, evenly distributed throughout. In the case of progesterone, pools with concentrations of 5-10 nmol/L, 10---20 nrnol/L and greater than 30 nmol/L are satisfactory, and cover the ranges of greatest clinical importance. Calculation of the CV of these results provides a simple doserelated profile of precision. Precision profiles calculated from the error in duplicate counts from one or more batches relate the error in the dose to the dose level. 40. 41, 45, 46 This method has the advantage of using all the sample, standard and QC data, and not just the QC pools. Profiles of successive batches can be used to define the 'envelope' of acceptable precision and provide a sensitive method for detecting changes in assay preci-sion. Within-batch precision profile measurements are useful during assay development to allow optimisation of the working range of the assay to suit clinical requirements. Changes in assay conditions for optimisation purposes can be monitored by precision profile measurements (Appendix 4).
The magnitude of the difference between within-and between-batch profiles reflects batch-to-batch assay variability and indicates the robustness of the assay. A robust assay shows little difference, whereas differences of twofold or more imply that the assay is sensitive to small changes in assay conditions, reagents, equipment or operator.
To obtain a reliable profile of assay precision the calculation should' be based on as many duplicate counts as possible (greater than 200), and the batches should consist of samples with progesterone concentrations distributed as evenly as possible within the range of the standard curve. Gross random errors in duplicates should be identified and initially excluded from the analysis. The response error relationship (RER) is obtained by linear regression of the variation in duplicate counts in the assay, and the counts. The error in dose at different dose levels can be derived from the RER and the slope of the dose-response curve. 40, 41. 45, 46 . Computer assistance is essential for the calculation of precision profiles and a current problem is the limited availability of suitable programs.
Laboratories not wishing to purchase or develop a complete data reduction package may find the technique proffered by Malan and Ekins (Appendix 4) satisfactory. It is desirable that the within-batch precision should be less than 10% over the clinically relevant range of 1D---40 nmol/L for progesterone; between-batch precision may be poorer. Examples of within-batch precision profiles of direct and extraction assays are shown in Fig. 2 . Both methods achieve good precision with a CV of less than 7% between 10 and 20 rimoUL, and less than 5% between 20 and 60 nmol/L, BIAS It is difficult for laboratories to assess bias by internal QC because sera with 'true' concentrations of progesterone are not generally available. Commercial material with an assigned level should not be considered as satisfactory targets unless the assigned value has been obtained by an independent validated reference method.
A partial index of assay bias can be obtained A=Standard curve; B=Precision profile. Progesterone (nmol / L) assay performance. Within-batch drift can occur, particularly with charcoal separation methods, and it is recommended that a pool be included at intervals to monitor drift and assess within-batch precision. TABLE 10 . In-house assay reagent costs from the accuracy of recovery from pools 'spiked' with different amounts of exogenous progesterone. Positive bias in sera with 'zero' levels is difficult to assess because of problems of obtaining serum which is free from progesterone; charcoal-treated serum may have a different matrix effect on the assay than untreated serum. To check bias at 'zero' dose, serum from men, or women taking contraceptive pills, with levels of less than one nmollL should give an undetectable result with binding values close to those of the zero dose standard. In extraction assays negative bias can result from incomplete extraction, and the efficiency and variability of the extraction step should be checked periodically. Positive bias can result from the effects of solvents and serum residues, and a blank or zero serum should be included in the assay to examine non-specific interference.
Cumulative sum techniques't': 44, 47 can also be employed to monitor drift in serum QC pools providing important criteria for assessing 
CRITERIA FOR ACCEPTABLE INTERNAL QC
The function of any internal QC programme is to assess overall performance and quickly and reliably highlight malfunctions. Experience has shown that realistic figures for between-batch CVs for progesterone QC lie in the region of 10---15% for levels below 10 nmollL, and 7·5-12% between 15 and 60 nmollL. These values can be held stable for many months without significant drift of mean values from initial targets. Within-batch CVs for progesterone assays are usually 2-3% lower over similar ranges. Criteria for deciding if a batch has passed QC scrutiny is dependent on the application of good ground rules tempered with common sense. 4O To do this intelligently it is necessary to understand thoroughly the purpose of the measurements. An experienced assayist may find clues in a suspect assay before even looking at QC results. Sudden changes in replication of duplicates (within-batch precision profile), percentage binding at zero dose, non-specific binding, or concentrations at 20, 50 and 80% inhibition of binding will all indicate reagent deterioration, faulty equipment or procedural error. An examination of the batch for drift may reveal problems with the separation system. Batches failing to meet the above criteria may be rejected before QCs are examined. It Progesterone assay guidelines 17 necessary, therefore, to keep clear records of these parameters which may be recorded on a QC data sheet together with the QC results. An example of a QC data sheet is shown in Table  -11 ; this may be modified to suit individual needs and can include, for instance, curve-fit parameters.
If no problems can be found with these general parameters, then QC results are examined. For batches which are only to be used for assessing the occurrence of ovulation, samples with unequivocal ovulatory or nonovulatory concentrations may be reported if either the low or middle range QC is marginally outside preset ranges. Samples in the range 15-30 nmol/L must be re-assayed. It must be remembered that in a QC programme with limits set at two standard deviations above and below the mean (95% confidence limits), then one in twenty batches will contain a control which falls outside these limits. If there are three control samples run once each in every batch, then one in seven may contain an outlier.
Batches in which two out of three control samples are outside the limits should be rejected. A similar system can be applied to multiples of levels of these controls in a single batch. For studies of the complete menstrual cycle, results from all three QCs should be within the pre-set range, and for extensive study of the luteal phase, the medium and high controls should be within the limits. If computer data reduction facilities are available, then suitable 'flags' can be positioned on chosen QC parameters designed to draw attention to any problems.
A common and difficult problem of internal QC is that of assessing long-term unobtrusive drifts of one or more controls away from the established mean value. Partial resolution can be achieved by using CUSUM procedures which are sensitive to consistent deviations away from pre-set targets (providing that these are correctly set), and sensitive to progressive changes in control levels. The Cardiff system'" is designed to allow the operator to select the number of batches passable before rejection occurs; the greater the deviation from the mean value, the fewer batches will be passed before rejection. This eliminates much of the guesswork and allows the assayist to employ consistent objective criteria over long periods of time.
A good QC system should not just consist of examination of a few pools with different concentrations of analyte, but should incorporate all data available from the assay. This will Quoted values arc usually the greater and smaller listed for each level. These values may be the results of different kits used in targetting. Assayists using a particular kit should obviously aim to achieve results in the range given for that method.
DPe target values are given to ± 3 SD. No definitions of the limits are given in any other control material assessed.
Prices
given arc those quoted in catalogues or obtained. prior to publication. by telephone. VAT is not included. Substantial discounts arc available from some manufacturers for large orders or programmed delivery.
It is possible to 'reserve' batches of suitable material from certain suppliers to ensure prolonged use of individual material. None of thc material tested is guarantced fur from the capability of transmitting viral infection. This is not an exhaustive list of all products availablc for the control of progesterone analysis.
Other products are available from both some of these and other manufacturers.
enable the assayist to make sensible decisions and provide a reliable service. The importance of not allowing QC decisions to be made solely by junior members of staff cannot be overemphasised. While junior members should be actively involved in QC procedures, decisions should always be made in conjunction with the supervisor.
In practice laboratories may not consistently achieve precision limits set out above, often because of rapid turnover of inexperienced staff. It is clearly not satisfactory to keep re-assaying samples in these circumstances, and it is preferable to institute a rigorous and effective training programme, perhaps sending samples to another laboratory until confidence is regained.
These suggestions are only guidelines. No laboratory running well on more stringent criteria should relax them. However, any laboratory which cannot meet these criteria should examine its assay, its quality control programme, and perhaps its internal organisation with a view to improvement.
MATERIALS FOR QUALITY CONTROL
For internal QC purposes material should be of human origin. Laboratories can prepare their own material by pooling patients' sera with known progesterone concentrations. These pools can be stored in aliquots and are stable for at least 6 months at temperatures below -20°C, and even longer at -70°C. The major disadvantage of this approach is the risk to health and the need to screen pooled serum for hepatitis B antigen. Recovery pools can be prepared by adding small volumes (50-200 IJ-L) of an ethanolic progesterone standard to 25 mL of serum with a basal progesterone of 5-10 nmol/L (i.e. a low concentration which can be measured precisely).
A number of commercial sources of Iyophilised material are available with assigned values (Table 12 ). These are relatively expensive, costing £1-2 per mL. The target of ranges quoted are usually based on consensus results obtained by a number of assay methods; they should not be regarded as 'true' target values unless confirmed by an independent method such as GCMS. Progesterone concentrations obtained by direct conventional extraction methods are shown in Table 12 .
Sera from Amersham (QAS 109 Obstetric and Gynaecology Control), Biorad (Lyphochek C-370-5) and Dade (TRIRAC BS65615) have very low progesterone levels, and should be Progesterone assay guidelines 19 considered unsuitable for monitoring assay performance. Materials from Becton Dickinson, DPC, Ortho and Wellcome have satisfactory levels and both extraction and direct methods compare favourably with those quoted by the manufacturer. The pools from Lyphocheck gave slightly higher binding in the direct assay than the zero standard (male serum), although satisfactory results were obtained from other manufacturers' pools with values of less than 5 nrnol/L. This apparent serum matrix effect in the direct assay suggests that certain commercial materials may behave differently from patient samples in the assay.
Regional policies for the provision of progesterone assay services Regional Scientific Officers were asked whether the Health Regions had policies for centralisation of progesterone assays, or for the provision of reagents by large laboratories to smaller laboratories within the regions. They were also asked if there were arrangements for obtaining advice on choice of kits or other reagents, on trouble-shooting, and for regular liaison between laboratories on aspects of radioimmunoassay quality control.
The responses showed that few regions had considered these points in detail. It is disappointing that there is such a general lack of co-ordinated policies within the health regions for the performance of progesterone assays, especially since these have been devolved from the Supraregional Assay Service. We consider that both considerable cost savings in the central provision of reagents and substantial improvements in overall laboratory performance would result from co-ordinated regional policies. Participants initially send details of their method to the organiser; they then receive six serum samples each month for analysis. Statistical analysis of the results is similar to that for thyroid and peptide NEQAS schemes. The bias of the laboratory from the all-laboratory trimmed mean (ALTM) , and the variation of the Progesterone assay guidelines 21 bias (VAR) are calculated for each laboratory in a 6-month running 'window'.
The NEQAS scheme is monitored by a Steering Committee composed of biochemists and endocrinologists; the purpose is to judge what constitutes adequate performance, and how to achieve it. In addition it ensures that the scheme is adequately assessing assay performance in the clinically important range set at 10-40 nmol/L for progesterone. Most NEQAS samples will be in this range, although occasionally samples will have low concentrations to assess baseline security, and the recovery of exogenous hormone will also be periodically examined.
The Steering Committee also sets minimum criteria for acceptable performance for laboratories participating in the scheme: what constitutes acceptable performance may change with time, and it is envisaged that performance should gradually improve. Unacceptable per-. formance for progesterone is currently defined as a bias of greater than ±20% of the ALTM, and a VAR of greater than 20%. Laboratories persistently outside these limits (i.e. for any 3 of the preceding 6 months), or persistently failing to return NEQAS results, will be contacted by letter by the organiser suggesting that attention is urgently required. If the poor performance cannot be accounted for or improved with whatever help is required from the organiser within a further 3 months, then data will be passed to the Advisory Panel on Quality Assurance in Chemical Pathology. By this time the problem will have existed for at least 6 to 9 months without effective corrective action! The Advisory Panel consists of four nominees of professional bodies, the Royal College of Pathology, Association of Clinical Biochemists, Association of Clinical Pathologists and the Institute of Medical Laboratory Sciences. The Panel will be consulted only when a participating laboratory has results frequently outside the limits set by the Steering Committee and when it fails to respond to those results and any advice the organiser may have offered.
It is important to note that the NEQAS scheme is confidential. Only the organiser is aware of the identity of any laboratory; neither the Steering Committee nor the Advisory Panel are aware of the identity of participating laboratories. It is also important to emphasise that help and advice about improving performance to acceptable limits is the predominant method of ensuring better results; the Advisory Panel is the last resort when laboratories cannot or will not respond.
Appendix 2: validation of steroid immunoassays
The scientific validation of steroid imrnunoassays is an essential means of ensuring that a fully developed assay produces the most precise, least biased results possible for that particular analytical system within the constraints of the user requirements. Consequently, the most important factors to consider when validating an assay are the range of results of clinical importance and the body fluid to be used.
CHOICE OF ANTISERUM, SEPARATION
SYSTEM, LABEL AND BUFFER
The choice of these fundamental aspects of the immunoassay system will depend on factors such as cost, availability, specificity of the antiserum, reliability and convenience of separation systems, equipment available and previous experience. If a kit method is chosen, the freedom to modify it is limited, and any modifications performed should be investigated with the same thoroughness as with an in-house method.
ASSESSMENT OF EXTRACTION EFFICIENCY
The efficiency of the solvent extraction step is most important; failure to optimise this stage will result in imprecision and bias. Both total recovery and variability of the recovery from batch-to-batch must be assessed. A simple method which gives reliable results, but which does not involve quench correction, is given below. The technique is best performed with a series of samples containing different quantities of endogenous steroid. Although in practice it is not necessary to re-purify labels for this experiment, material with high chemical and radiochemical purity is necessary. Tritiated steroids must be used for the experiments, as the behaviour of iodinated steroids is not identical with that of the endogenous hormone. plasma to the extraction tubes, mix well, and incubate at 37°C for 45 min. Allow to cool to room temperature, add the solvent and extract. Separate the phases and place 75% of the solvent from each of the extraction tubes (R) into six separate clean scintillation vials. From the extraction tubes (B) transfer the same volume of solvent into the scintillation vials (T) to which tritiated steroid has already been added. Evaporate the solvent from all scintillation vials, add scintillation fluid and measure the radioactivity.
Compute the mean radioactivity in each group: mean radioactivity in recovery tubes (R) mean radioactivity in total tubes (T) volume of solvent added (V) volume of solvent removed (A).
Correct the counts in the recovery tube for total solvent volume: As a rough guide, the labelled antigen mass may be ascertained by using an amount similar to the detection limit of the assay. This may be titrated against a series of antiserum dilutions. The least dilute antiserum concentration which binds~% of the labelled antigen is a reasonable starting point for assay development.
The early optimisation of the separation system is essential. A system is required which will absorb or otherwise separate all the unbound material from all the antibody-bound material without affecting the equilibrium. Experiments with the separation system need to be performed both in the presence and absence of antiserum to assess the non-specific binding. Variations in the concentrations of reactants, incubation times and temperatures must be examined to ensure conditions where nonspecific binding is minimal and both specific and non-specific binding is stable.
INTRODUCTION OF QUALITY CONTROLS
AND VALIDATION
At this stage the internal quality-control scheme should be introduced, either by using pooled serum or plasma or commercial Iyophilised material. The method may then also be tested for linearity of dose-response, recovery of added unlabelled steroid to pools, and for matrix effects. It is also important to establish the behaviour of the system at low analyte concentration by assaying zero hormone concentration sera and buffer, both' with and without added steroid. Should any of these experiments fail to reach pre-established criteria then alterations in the assay system must be made. Matrix effects may be studied by assaying the same samples with and without anticoagulant, using pregnancy samples, and performing recovery experiments in charcoalstripped serum.
MEASUREMENT OF PRECISION AND BIAS
A formal three-level internal quality-control programme should now be established. Pooled serum stored frozen in aliquots or commercial Iyophilised products may be used. Arrangements to commence assaying NEQAS samples should be finalised, and NEQAS samples assayed to establish that the method is in agreement with the consensus.
With good QC performance established, the within-and between-batch precision should be assessed at at least six concentrations of ana-Iyte, and plotted as a precision profile. It should be noted that different profiles may be obtained for quality-control (especially commerciallyophilised material) and patients' sam-Progesterone assay guidelines 23 pies. Precision profiles (Appendix 4) may also be assessed using duplicates of patients' samples.
FINALISING PRECISION AND BIAS STUDIES
Reproducibility is further assessed at this stage both by analysis of samples from previous batches and additional recovery experiments so that any final optimisation may be achieved. At this stage it is imperative to ensure that the method can give adequate results with other members of staff, especially those responsible for its day-to-day use. No statistically significant difference should occur between results obtained by different operators. Differences can occur because of inattention to important details; careful teaching of basic principles and operational procedures is essential for the continued production of high quality results.
INTRODUCTION INTO ROUTINE USE
When the method shows satisfactory precision and minimum bias, reference ranges should be established for the conditions in which it is to be used clinically. This will necessitate liaison with clinicians, and it offers an opportunity to express the strengths and weaknesses of the method so that the service is used to maximum effect when introduced routinely.
Appendix 3: steroid kit evaluations
Over the last few years independent evaluations of kit methods for analysing steroid hormones in serum or plasma have been carried out by members of the appropriate NEQAS schemes. Each report follows the same formatdescription of reagents provided, packaging, methodology, cost, precision, bias with reference to NEQAS samples, comparison with other methods and the strengths and weaknesses of the kit in routine laboratories.
The evaluations follow a set protocol whereby six laboratories, currently using a variety of methods, commented on the new kit and assayed samples provided by NEQAS and from their own clinics. Comments from manufacturers or distributors were also sought, and included where appropriate.
The evaluations have their limitations. Each is dated and readers are advised to check with suppliers to determine if any modifications were subsequently introduced. Furthermore, no account is taken of the kit's performance in a laboratory that has had time to familiarise itself with any idiosyncrasies. However, the evalua-
